Aurora Financial JournalVicore Pharma Holding AB (VICO.ST)
Nasdaq Stockholm · Financial statements, TTM figures and earnings dates
In fiscal year 2023 (ended December 31, 2023), Vicore Pharma Holding AB reported revenue of SEK 0 and net income of −SEK 310.9M. Annual financial statements are available for fiscal years 2021 to 2023, taken from the company's ESEF annual reports (IFRS).
Open interactive financials →Key financials
| SEK | FY2023 2023-12-31 | FY2022 2022-12-31 | FY2021 2021-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | SEK 0 | SEK 0 | SEK 0 |
| Gross profit | SEK 0 | SEK 0 | SEK 0 |
| Operating income | −SEK 321.5M | −SEK 290.7M | −SEK 294.8M |
| Net income | −SEK 310.9M | −SEK 288.4M | −SEK 296.5M |
| Diluted EPS | −SEK 3.22 | −SEK 3.99 | −SEK 4.25 |
| Cash flow | |||
| Operating cash flow | −SEK 249.6M | −SEK 299.9M | −SEK 265.2M |
| Balance sheet | |||
| Cash and equivalents | SEK 333.6M | SEK 256.8M | SEK 294.2M |
| Total assets | SEK 497.8M | SEK 338.0M | SEK 451.2M |
| Total liabilities | SEK 42.4M | SEK 48.9M | SEK 67.9M |
| Shareholders' equity | SEK 455.4M | SEK 289.1M | SEK 383.3M |
TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.
Annual reports
More on the interactive page
The full VICO.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.
Open VICO.ST financials →